Zomedica Unveils TRUFORMA® Research at Major Veterinary Conference

Zomedica Corp. (NYSE American: ZOM) presented new research on their TRUFORMA® Bulk Acoustic Wave (BAW) platform at the American College of Veterinary Internal Medicine (ACVIM) Forum. The findings highlight the platform’s superior diagnostic capabilities for feline hyperthyroidism, surpassing conventional CLIA methods.

Dr. Stefanie DeMonaco, Associate Professor at Long Island University, noted the BAW system's enhanced sensitivity in low ranges, ensuring accurate diagnosis even with non-thyroidal illness. These insights reaffirm TRUFORMA's role in precise veterinary diagnostics, offering rapid, reliable results directly at the point-of-care.

Zomedica also supports educational programs at ACVIM, reinforcing its commitment to advancing veterinary diagnostics and therapeutics. The veterinary health company aims to expand its TRUFORMA platform with additional assays, targeting a vast potential market.